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Abstract 
In this paper, we develop a theoretical contribution towards the understanding of the 
complex  behavior  of  conjoint  tumor-normal  cell  growth  under  the  influence  of           
immuno-chemotheraputic agents under simple immune system response. In particular, 
we consider a core model for the interaction of tumor cells with the surrounding normal 
cells. We then add the effects of a simple immune system, and both immune-suppression 
factors and immuno-chemotherapeutic agents as well. Through a series of numerical 
simulations, we illustrate that the interdependency of tumor-normal cells, together with 
choice of drug and the nature of the immunodeficiency, leads to a variety of interesting 
patterns in the evolution of both the tumor and the normal cell populations. 
Key words: Aging, tumor cell dynamics, normal cell dynamics, tumor-normal cell interactions, 
chemotherapy, Immune system, Immunotherapy, Immunodeficiency 
Introduction 
Every  day,  clinical  and  experimental  studies 
provide evidence of new features that can influence 
cancer  dynamics  and  its  treatment  methodologies 
[1-4].  Ongoing  research  efforts  aim  to  provide  a 
clearer  picture  of  the  evolution  of  the  tumor  and 
normal cells with the objective of improving cancer 
treatment protocols. 
During cancer progression, tumor cells interact 
with  the  surrounding  environmental  components 
such  as  normal  cells,  immune  cells  or  therapeutic 
agents that have been externally added to the system. 
The  nature  of  the  tumor-environment  interaction  is 
complex and depends upon many factors such as host 
age, sex, and many more. They are all key factors that 
can lead to complex patterns of tumor cell evolution. 
Considering the tumor-environment interaction, 
it has already been demonstrated that the growth of 
normal and tumor cells are co-dependent due to their 
biochemical  and  biomechanical  interactions  [5-12]. 
Additionally,  researchers  have  experimentally  ex-
plored  the  interaction  of  tumor  cells  with  the  host 
immune  system  and  the  suppressive  effects  of  the 
immune  cells  in  tumor  progression  [13-18].  Experi-
mental evidence demonstrates that there is an altera-
tion of the level of immune components during the 
various stages of cancer growth. This underlines the 
key role of the immune system in cancer dynamics [1, 
19].  Understanding  the  intrinsic  growth  of  tumor 
cells,  together  with  the  interaction  with  their  sur-
roundings,  has  led  to  several  single  and  mul-
ti-therapeutic strategies to modulate and control the 
growth of these cells.  
We can, however, examine the evolution of tu-
mor and normal cells and complexity of the system 
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through the use of computational and mathematical 
modeling  and  simulation.  For  example,  the  interac-
tion of tumor cells with surrounding normal cells was 
first mathematically introduced by Witten [20-23]. The 
interaction  of  immune  system  and  different  thera-
peutic agents with tumor cells has been theoretically 
modeled  and  studied  by  several  research  groups 
[24-30].  
In this paper, we make use of Witten’s [23] core 
tumor-normal cell model. However, we modify it as 
follows. First, we model the interaction of the immune 
system  with  the  conjointly  growing  tumor-normal 
cells. Then, we assume a deficiency in the immune 
system due to the presence of immune-suppressing 
factors such as viruses. Additionally, we add a dif-
ferent therapeutic approach to this modified model. 
We then investigate the evolution of normal and tu-
mor cells through a series of computational simula-
tions.  Finally,  we  offer  subsequent  biological  inter-
pretations of the simulation results. 
Building the Mathematical Model 
Introducing the Conjoint Core Model 
In the core model, both the normal and tumor 
cells  independently  increase  according  to  a  logistic 
growth  law  (other  types  of  independent  growth 
model may be used). The interaction of tumor with 
normal and normal with tumor cells is described by 
the second term in the model where the normal cells 
are denoted by N and the tumor cells are denoted by 
T. Thus, the original core model [20-23] expresses one 
possible  dynamics  for  the  interplay  of  normal  and 
tumor cells and it is given by the following system of 
equations: 
 
where T, N, KT, KN, rT, rN are the total number of tumor 
cells, the total number of normal cells, the carrying 
capacity of the tumor cells, the carrying capacity for 
the normal cells, and the per capita growth rate for the 
tumor and normal cells respectively and κ is the tu-
mor-normal cell coupling constant. The second terms 
in  each  equation  represent  the  nor-
mal-tumor/tumor-normal  cell  interactions.  Here,  β 
has the units of 1/time (where time is measured in 
arbitrary units depending upon the timescale of in-
terest in the problem) and ρ0 is measured in units of 
cells. T* is the critical number of tumor cells and as T 
exceeds the critical size T*, the tumor cells increase 
their  ability  to  inhibit  normal  cell  growth.  This  be-
havior is illustrated in Figure 1. Figure 1A, shows the 
independent growth  of  the  normal  and  tumor  cells 
(no  interactions).  However,  in  the  conjoint  growth 
illustrated in Figure 1 B, we can see the dependency 
between the cell populations. As the size of the tumor 
cell population, T, exceed the critical size, T*, the size 
of the normal cell population, N, begins to decrease.  
 
 
Figure 1: Green curve: Evolution of normal cell population. Red curve: Evolution of tumor cells. Simulation pa-
rameters: r N=0.4, r T =0.3, K T=1.2. 10
6, K N=10
6. A: There is no interaction between normal cells and tumor cells (both 
populations undergo logistic growth), κ=0, β=0. B: Normal and tumor cells are allowed to interact with each other, κ 
=0.028, β =1, ρ0=1, ρ1=1000, T*=3.10
5, N0=1, T0=1. As the size of the tumor cells T exceed the critical size, T* (dashed 
line), the size of normal cells N starts decreasing. 
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Immune-Tumor interaction 
Panetta  &  Kirschner  mathematically  modeled 
the interaction of tumor cells with the immune system 
and immune-therapeutic agents [31, 32]. This model, 
which  has  been  used  in  other  studies  [33,  34],  ex-
plained clearly the equilibrium of the tumor-immune 
system as well as the oscillatory behavior of the tumor 
size around the equilibrium. In this paper, we add the 
concepts of the interaction of the immune system es-
tablished  by  Panetta  and  Kirschner  to  our  conjoint 
growth  model.  As  explained  in  Kirschner’s  model, 
two variables are considered to be the main immune 
system  components:  the  first  is  activated  im-
mune-system cells (effector cells) including T cells and 
other immune cells that are cytotoxic to tumor cells. 
E(t) represents the effector cells in the modified model 
equations  below.  The  second  immune  system  com-
ponent is the concentration of IL-2, which is the main 
cytokine responsible for T cells activation, growth and 
differentiation at the tumor site. This variable is ex-
pressed by I(t). 
The  loss  of  tumor  cells,  due  to  the  im-
mune-effector  cells  can  be  characterized  with  a 
Michaelis-Menten interaction term, aET/(g2 + T). Here, 
‘a’ is the rate of clearance of tumor cells as a result of 
these two populations and g2 is the half-saturation for 
cancer clearance. Also, the activation happens because 
of the presence of IL-2 hormones and is given by the 
term p1EI/(g1+ I). This is also a Michaelis-Menten term. 
Here p1 is the proliferation rate of immune cells and g1 
is  the  half-saturation  for  the  proliferation  term.  To 
express  the natural  death  of  effector  cells,  the  term 
-µ3E is added. In this term µ2 is the death rate of the 
immune cells. The change in concentration of IL-2 is 
expressed as: p2TE/(g3 + T), which is the activation due 
to the presence of the tumor. In this term, p2 is the 
production rate of the effector molecules and g3 is the 
half-saturation of production. Finally, -µ2I, is the nat-
ural loss of IL-2 by the rate of µ2. 
Adding Chemo/Immuno-Therapy to the Im-
mune-Tumor Interaction 
Many factors can be considered to be immune 
suppression  factors,  including  immune-suppression 
viruses. These viruses can infect the activated immune 
cells. As a result of this infection, the population of 
activated cells decreases and this leads to a weakened 
immune  system.  In  such  a  case,  the  treatment  can 
consist of immune boosting drugs such as Interleu-
kin-2  (IL-2)  [35].  Kirschner  [36,  37]  mathematically 
characterized  the  general  interaction  of  the  Human 
Immunodeficiency Virus and activated immune cells. 
The presence of immune suppression factors reduces 
the efficiency of the immune system in battling tumor 
cells. These same mathematical terms are, thus, added 
to  our  model  to  explain  a  simple  possible  immune 
deficiency [35]. Similar to the approach of Kirshner, 
the production source of virus, V(t), can be introduced 
as ηV/(b+V) where η is the production rate and b is the 
saturated  term.  -µ1V  expresses  the  natural  death  of 
viruses at rate of µ1. The interaction between effector 
cells and viruses can reduce the size of both popula-
tions with different rates. This is expressed as: - αVE 
and -γVE to illustrate the interaction between virus 
and effector cells. As a result of this interaction, the 
immune effector cells decrease the population of vi-
ruses at rate α. Additionally, viruses infect some of the 
effector cells and, therefore, the population of unin-
fected effector cells decreases at the rate γ. 
Treatment Characterizations  
To control cancer progression, many approaches 
can  be  implemented,  among  them  chemotherapy, 
immunotherapy or some combination of the two. The 
enhancement  of  the  immune  system  by  immu-
no-therapeutic agents that directly boost the number 
of T cells has a key role in the reduction of both the 
number of tumor cells and viruses. Chemotherapeutic 
agents  can  kill  the  tumor  population  in  a 
dose-dependent manner [38, 29]. Feizabadi and Wit-
ten  [28]  have  investigated  the  effect  of  the  chemo-
therapeutic agents on a conjoint system of tumor and 
normal cells. However, chemotherapeutic agents are 
cytotoxic not only to tumor cells, but also to normal 
and activated cells as well. Clinical evidence also in-
dicates that some of the anticancer agents can control 
the replication of viruses in a dose-dependent man-
ner. Some data supports and some discourage the use 
of  anticancer  agents  for  immuno-deficient  virus 
treatment. On the one hand, some drugs have strong 
anti-activity  virus  effects,  but  not  the  ability  to  kill 
rapidly proliferating tumor cells. On the other hand, 
some of the anti-proliferating drugs may not have a 
positive  effect  on  controlling  viruses  [39].  Conse-
quently,  it  is  obvious  that  therapeutic  potential  de-
pends upon the impact and the cross-toxicity of the 
drug  on  different  components  of  the  system. 
Knowledge of these pharmacokinetic interactions can 
improve  the  future  architecture  of  both  drugs  and 
treatment strategies.  
Gardner  [40],  first  suggested  the  general  term 
aφ(1-e- ξMC)φ for φ = T, N, E as a means of describing as 
drug interaction term. In our model, we have consid-
ered  cellular  interaction  with  chemotherapeutic 
agents and we have allowed them to have some de-
gree of toxicity to T, N, and E cells. Additionally, the 
immunotherapeutic  agent  is  described  by  the  term Int. J. Biol. Sci. 2011, 7 
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aEE(1-e ξMI) and it acts as an immune-boosting agent. In 
the interaction terms, the constants MC and MI rep-
resent  the  chemotherapy  and  immunotherapy  drug 
concentrations and ξ is linked to the drug pharmaco-
kinetics and is assumed to have the value ξ = 1 in this 
preliminary study [28, 29]. 
ODE Model: Mathematical Construction of the 
Modified Model 
Combining all of the aforementioned interaction 
terms,  the  evolution  of  the  full  system  can  be  ex-
pressed as follows: 
 
 
 
The  evolution  of  the  above  full  system  is  dis-
cussed in the following sections. 
Model Simulation 
Simulation of the compartmental evolution was 
carried  out  using  Mathematica  V7.0.  Our  choice  of 
parameters is based on values previously introduced 
or obtained from references in the literature. The cita-
tion for each parameter along with the associated pa-
rameter values is given in Table 1. However, given the 
generality  of  the  model,  alternate  parameter  values 
may also be implemented allowing the user to further 
investigate the kinetics of the various system compo-
nents.  
Table 1: Simulation Parameters 
Parameter  Units  Description  Estimated Value  Reference Source 
rT  Time-1  Growth rate for the tumor cells  0.3  [28] 
KT  Cells  Carrying capacity of tumor cells  1.2*106  [28] 
β  Time-1  Normal-tumor cell interaction rate  01  [28] 
ρ0  Cells  Interaction clearance term  1  [28] 
ρ1  Cells  Half-saturation for interaction  1000  [28] 
a  Time-1  Cancer clearance term  1  [31] 
g2  Cells  Half-saturation for cancer clearance  105  [31] 
rN  Time-1  Growth rate for the normal cells  0.4  [28] 
KN  Cells  Carrying capacity of normal cells  106  [28] 
κ  Time-1  Tumor-normal cell interaction rate  0-0.028  [28] 
T*  Cells  Critical size of tumor  3*105  [28] 
c  Time-1  Antigenicity  0.005  [31] 
µ2  Time-1  Death rate of immune cells  0.03  [31] 
p1  Time-1  Proliferation rate of immune cells  0.1245  [31] 
g1  Cells  Half-saturation proliferation term  2*107  [31] 
p2  Time-1  Production rate of effector molecules  5  [31] 
g3  Cells  Half-saturation of production  30  [31] 
µ3  Time-1  Half-life of effector molecules  10  [31] 
µ1  Time-1  Death rate of viruses  0.03  - 
b  Viruses  Half-saturation of virus population  5  - 
α  Time-1  Effector cell-virus interaction rate  2.5*10-4  - 
η  Time-1  Production rate of viruses  3*104  - 
γ  Time-1  Virus-effector cell interaction rate  0.005  - 
  Concentration-1  Pharmacokinetic parameter  1  [29] 
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Figure 2: A: Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2 
Concentration. The common parameters are the same amount as Figure 1. The new parameters are: a=1, g2=10
5, 
c=0.005, µ2=0.03, p1=0.1245, g1=2*10
7, p2=5, g3=30, µ3=10. In this figure, Red curve represents the interaction with 
the immune system. The Black curve represents the interaction of the system with just chemotherapeutic agents 
when aT[1-exp
(-MC)]=0.05, and aN[1-exp
(-MC))=aE[1-exp
(-MC)]=0.01. The Orange curve represents the interaction with the 
chemotherapeutic agent when the killing effect of the chemotherapeutic agents on effector and normal cells is 
minimum. In this case, aT[1-exp
(-MC)]=0.05 and aN[1-exp
(-MC)]=aE[1-exp
(-MC)]=0.001. The Blue curve represents the 
interaction of the system with the chemotherapeutic agents with the same parameters as the orange graph and the 
immune boosting agents where aEE[1-exp
(-MI)]=0.002. The Green curve represents the same case as the blue case with 
higher dosage of the immune boosting drugs, aEE[1-exp
(-MI)]=0.004. As explained in the text, the most effective 
therapy is the case associated to the implementation of the chemotherapeutic agents that majorly kill tumor cells 
together with effector cells boosting drugs. Some oscillatory behavior can be seen though around the equilibrium 
when both agents are implemented before reaching the final equilibrium. 
 
 
The behavior of tumor, normal, effector cells and 
IL-2 concentration in a conjoint model is studied using 
different  simulation  assumptions.  In  Figure  2,  the 
behavior  of  the  components  of  the  system  is  illus-
trated for the case where the system of tumor-normal 
cells interacts with the host immune system compo-
nents.  
As the system of tumor and normal cells inter-
acts  with  the  immune  cells,  the  amount  of  effector 
cells and the concentration of IL-2 are increased due to 
the presence of the tumor cells, Figure 2C and 2D. As 
a result of the cancer clearance effect of the effector 
cells, the population of the tumor cells decreases and 
the population of the normal cells increases as com-
pared with the dynamics illustrated in Figures 2A, 2B. 
Chemotherapeutic  agents  are  introduced  into  the 
system of tumor-normal cells that are already inter-
acting with the immune system and the evolution of 
the system components changes. We first consider the 
case in which the chemotherapeutic agent kills tumor 
cells. These agents are also assumed to kill normal and 
immune cells due to their toxicity. However, it is as-
sumed that the killing rate of the chemotherapeutic 
agent is higher for the tumor cells than for the normal 
and the effector cells. Therefore, we observe a slight 
decrease in the size of the tumor cell population. As Int. J. Biol. Sci. 2011, 7 
 
http://www.biolsci.org 
705 
the size of the tumor cell population decreases, the 
population of the effector cells and the IL-2 levels de-
crease as well. The Figure 2 black curves illustrate the 
chemotherapeutic interaction.  
Ideal chemotherapeutic agents (Orange curves in 
Figure 2) are agents that are capable of killing signif-
icant numbers of tumor cells with very minimal ef-
fects on the normal and the effector cell populations. 
In this case, the shrinkage of tumor cells is significant. 
The population of the tumor cells decreases and both 
the tumor cells and normal cells experience oscilla-
tions  around  their  equilibrium  during  the  chemo-
therapeutic  interaction.  If  we  then  add  additional 
immunotherapeutic  agents,  the  final  population  of 
tumor cells decreases significantly. However, the in-
teraction  of  the  tumor  cell  population  with  immu-
no-chemotherapeutic  agents  exhibits  an  increased 
amplitude of the oscillation before reaching a steady 
state behavior (Blue and Green curves in Figure 2). 
This  shrinkage  is  combined  by  an  oscillatory 
behavior  with  small  amplitude  in  oscillation.  The 
system expresses a better response in terms of a re-
duction  in  the  size  of  the  tumor  cells,  when  in  the 
presence  of  chemotherapeutic  agents,  and  the  im-
munotherapy is added. In the current case, the final 
size  of  the  tumor  cell  populations  is  significantly 
smaller. However, the more effective immunothera-
peutic agents cause oscillations with larger amplitude 
before reaching to a steady state behavior. 
In  our  final  case,  we  consider  the  scenario  in 
which the immune system has reduced effectiveness. 
In this particular case, we assume that the reduction is 
due  to  a  viral  load.  Due  to  the  existence  of an  im-
mune-suppressant, the population of the effector cells 
at the steady state decreases (Figure 3D) and, subse-
quently, the population of the tumor cells increases 
(Figure 3A). Also, in the immune-deficient system, the 
growth of the effector cells demonstrates a delayed 
onset as compared to the system with no deficiency. 
Additionally, we observe that the growth of effector 
cells is slower in the presence of this deficiency. In the 
absence of any immune deficiency, we simulated the 
behavior  of  the  tumor  cells  under  an  im-
mune-chemotherapeutic  agent.  As  discussed  above, 
under  the  effect  of  the  immuno-chemotherapeutic 
drugs, the population of effector cells decreases, while 
there  is  an  oscillatory  behavior  before  reaching  the 
steady  state.  In  the  presence  of  an  immune  system 
deficiency,  in  order  to  reach  a  nearly  equivalent 
steady  state  after  therapy,  we  first  used  the  same 
amount  of  chemotherapy  and  increased  the  immu-
notherapeutic agent. We observe that a much larger 
amount of this same agent is needed in order for the 
system  to  approach  the  same  steady  state  (Figure 
3-Green).  Alternatively,  in  order  to  reach  the  same 
steady state, in the presence of any limitation in the 
dosage  of  the  immuno-therapeutic  agent,  one  can 
slightly increase the amount of immuno-therapeutic 
agent  together  with  a  simultaneous  increase  in  the 
amount  chemotherapeutic  agent  (Figure  3, 
Dashed-Green). 
Closing Remarks 
In this work, we modified Witten’s [23] conjoint 
normal-tumor cell model in order to incorporate the 
presence of a simple immune system. The evolution of 
the system variables was investigated via computer 
simulation. Various cases were considered. We first 
considered the effect of a chemotherapeutic agent on 
the system. We investigated different therapeutic ap-
proaches to control the size of the tumor cell popula-
tion. We then considered the possibility of the exist-
ence of a virally induced deficiency in the immune 
system  function.  In  this  scenario,  the  deficiency  di-
rectly affected the behavior of tumor and normal cells 
as well as the immune system components. Among 
the  possibilities,  chemotherapeutic  together  with 
immunotherapeutic  agents  demonstrated  the  best 
outcome in terms of reducing the size of the tumor in 
the absence of any deficiency. In the presence of im-
mune  deficiency  factors,  even  the  most  successful 
therapeutic agents needed to be re-evaluated to obtain 
similar outcomes in terms of the reduction in size of 
the tumor cells, as compared to a properly functioning 
immune  system  in  the  absence  of  any  deficiency. 
Simulations  demonstrated  that  either  the  level  of 
immunotherapeutic  agents  should  significantly  in-
crease or the level of chemotherapeutic together with 
immunotherapeutic agents should increase. This in-
crease may control the size of the tumor cell popula-
tion,  but  the  toxicity  of  chemotherapy  reduces  the 
immune  system  and  the  ability  to  battle  the  virus, 
which may subsequently lead to death as a result of 
infection. 
In an attempt to control the size of the tumor cell 
population, through different therapeutic protocols, it 
is necessary to first evaluate any factors, which may 
suppress the functionality of the immune system. Se-
cond, the nature of the therapeutic agents and the way 
that they interact with normal, tumor, immune cells 
and  immunodeficiency  factors  needs  to  be  investi-
gated prior to implementation. In short, more infor-
mation regarding the intrinsic interaction among dif-
ferent types of cells together with the interaction of 
each group of cells and externally added agents can 
lead  to  selecting  a  better  treatment  approach  and 
reaching a better outcome in the reduction and control 
of the cancer. Int. J. Biol. Sci. 2011, 7 
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Figure 3: In this figure the system behavior under the influence of immunodeficiency viruses is investigated. A: 
Evolution of Tumor cells. B: Evolution of normal cells. C: Evolution of effector cells. D: Evolution of IL-2 Concen-
tration. E: Evolution of Virus. Same common parameters are implemented as before. The specific parameters are 
η=3*10
4, b=5, γ=0.005, α=2.5*10
-4, µ1 =0.03. The Red curve represents the behavior of the components in the 
presence of the virus. Black: General chemotherapy is then introduced and then improved to the chemotherapeutic 
agents with major killing effects on tumor cells. Blue: the effector boosting drugs is added. Green: the dosage of the 
immune boosting drugs is significantly increases aEE[1-exp
(-MI)]=0.02 to almost reach to the equilibrium of the system 
in the absence of any viruses. In dashed-Green line, instead of significantly increasing the dosage of immune boosting 
drugs to reach to the equilibrium discussed in Figure 2, both chemotherapeutic and immunotherapeutic drugs was 
increased, aEE[1-exp
(-MI)]=0.01, aT[1-exp
(-MC)]=0.05. 
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